NAD+ & Cellular Aging

The molecule, and its two jobs: NAD+ works in two modes at once. In its redox role it ferries electrons through the mitochondrial engines that make cellular energy — the original, ancient job, present in every living cell. In its signaling role it is consumed as fuel by enzyme families that regulate aging-relevant processes — sirtuins (the seven-gene family tied to DNA repair and metabolic regulation) and PARPs (DNA-strand-break repair), which spend NAD+ as they work. The age-related decline is real and measured in human tissue; its magnitude varies by tissue and study, and the popularized '~50% by middle age' figure carries real uncertainty — the direction is solid, the decimal points are not.

The fame arc: NAD+'s celebrity traces a specific research path — sirtuin genes extending lifespan in yeast, the resveratrol moment (the red-wine molecule that was supposed to activate sirtuins and didn't cleanly survive its own replication era), and the modern precursor boom that followed. The science underneath is genuinely interesting: NAD+-dependent enzymes really do connect energy status to repair and aging biology. What the arc added was a timeline — 'the aging pill is five years away' — that the trials have never supported. The molecule is real; the schedule was marketing.

The precursors, and the fine print: because the NAD+ molecule itself is too large to usefully supplement, the industry sells its building blocks — NR (nicotinamide riboside), with the most published human trials, and NMN (nicotinamide mononucleotide), the more famous sibling. What's proven: both reliably raise blood NAD+ levels in human trials — the biomarker effect is solid. What's not: any demonstrated change in aging outcomes, because no trial has run the decades that would take. The small human signals to date — modest blood-pressure and arterial-stiffness improvements with NR in some studies, nulls elsewhere — are exactly the size 'early' means. And the regulatory wrinkle the shelf skips: the FDA stated in 2022 that NMN is under investigation as a drug, excluding it from the dietary-supplement definition — leaving NMN products in a gray zone buyers should know they're in.

The free lever, and the honest close: exercise raises NAD+ — the adaptation your body already owns, free, with decades of outcome evidence behind the practice even where the NAD+ mechanism is still being mapped. Time-restricted eating shows mild, debated effects; the de-novo synthesis path from tryptophan runs quietly regardless. The category summary this page owes you: biomarker-proven, outcome-unproven, long-term high-dose safety uncharacterized — and the fear-marketing pattern ('your NAD is collapsing') sells the problem before the evidence sells the fix. The frontier is worth following. The bottle is worth waiting on.

• NAD+ has two jobs: mitochondrial energy shuttling, and fuel for aging-relevant signaling enzymes.
• Levels decline with age — direction solid, magnitudes tissue-specific and debated.
• NR and NMN reliably raise blood NAD+ in human trials — the proven part.
• No human trial has tested whether raising NAD+ changes aging outcomes — the open part.
• NMN sits in an FDA gray zone: under drug investigation, excluded from the supplement definition.
• Exercise raises NAD+ — the free lever with the outcome record the bottles lack.